Dénes Judit, Kasuki Leandro, Trivellin Giampaolo, Colli Leandro M, Takiya Christina M, Stiles Craig E, Barry Sayka, de Castro Margaret, Gadelha Mônica R, Korbonits Márta
Department of Endocrinology, William Harvey Research Institute, Barts and the London School of Medicine, Queen Mary University of London, London, United Kingdom; Semmelweis University, School of PhD studies, Doctoral School of Clinical Medicine, Budapest, Hungary.
Endocrinology Unit, Clementino Fraga Filho University Hospital, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.
PLoS One. 2015 Feb 6;10(2):e0117107. doi: 10.1371/journal.pone.0117107. eCollection 2015.
Patients with germline AIP mutations or low AIP protein expression have large, invasive somatotroph adenomas and poor response to somatostatin analogues (SSA).
To study the mechanism of low AIP protein expression 31 sporadic somatotropinomas with low (n = 13) or high (n = 18) AIP protein expression were analyzed for expression of AIP messenger RNA (mRNA) and 11 microRNAs (miRNAs) predicted to bind the 3'UTR of AIP. Luciferase reporter assays of wild-type and deletion constructs of AIP-3'UTR were used to study the effect of the selected miRNAs in GH3 cells. Endogenous AIP protein and mRNA levels were measured after miRNA over- and underexpression in HEK293 and GH3 cells.
No significant difference was observed in AIP mRNA expression between tumors with low or high AIP protein expression suggesting post-transcriptional regulation. miR-34a was highly expressed in low AIP protein samples compared high AIP protein adenomas and miR-34a levels were inversely correlated with response to SSA therapy. miR-34a inhibited the luciferase-AIP-3'UTR construct, suggesting that miR-34a binds to AIP-3'UTR. Deletion mutants of the 3 different predicted binding sites in AIP-3'UTR identified the c.*6-30 site to be involved in miR-34a's activity. miR-34a overexpression in HEK293 and GH3 cells resulted in inhibition of endogenous AIP protein expression.
Low AIP protein expression is associated with high miR-34a expression. miR-34a can down-regulate AIP-protein but not RNA expression in vitro. miR-34a is a negative regulator of AIP-protein expression and could be responsible for the low AIP expression observed in somatotropinomas with an invasive phenotype and resistance to SSA.
携带种系AIP突变或AIP蛋白表达水平低的患者患有大型侵袭性生长激素腺瘤,且对生长抑素类似物(SSA)反应不佳。
为研究AIP蛋白表达水平低的机制,分析了31例散发的生长激素腺瘤,其中AIP蛋白表达水平低(n = 13)或高(n = 18),检测了AIP信使核糖核酸(mRNA)以及预测可与AIP的3'非翻译区(UTR)结合的11种微小核糖核酸(miRNA)的表达情况。采用野生型和AIP-3'UTR缺失构建体的荧光素酶报告基因检测法,研究所选miRNA对GH3细胞的影响。在HEK293和GH3细胞中过表达和低表达miRNA后,测量内源性AIP蛋白和mRNA水平。
AIP蛋白表达水平低或高的肿瘤之间,AIP mRNA表达未观察到显著差异,提示存在转录后调控。与AIP蛋白表达水平高的腺瘤相比,miR-34a在AIP蛋白表达水平低的样本中高表达,且miR-34a水平与SSA治疗反应呈负相关。miR-34a抑制荧光素酶-AIP-3'UTR构建体,提示miR-34a与AIP-3'UTR结合。AIP-3'UTR中3个不同预测结合位点的缺失突变体确定c.*6-30位点参与miR-34a的活性。在HEK293和GH3细胞中过表达miR-34a导致内源性AIP蛋白表达受到抑制。
AIP蛋白表达水平低与miR-34a高表达相关。miR-34a在体外可下调AIP蛋白表达,但不影响RNA表达。miR-34a是AIP蛋白表达的负调节因子,可能是侵袭性表型且对SSA耐药的生长激素腺瘤中AIP表达水平低的原因。